Lioi Susanna

Dott.ssa Susanna Lioi

Linea di ricerca: UOS Retina Medica

Principali specializzazioni: Degenerazione maculare legata all'età, Difetti di Refrazione Oculari, Distacco di retina, Ipovisione e Riabilitazione Visiva, Occlusione Venosa Retinica, Retinopatia Diabetica

Attività medica: La Dott.ssa Lioi dal 2010 svolge attività clinico scientifica nell’Unità Operativa di ricerca “Retina Medica” presso l’IRCCS Fondazione G.B. Bietti.
Partecipa a numerosi trials clinici internazionali come Study Coordinator e Co-investigator .
I suoi maggiori interessi riguardano l’ortottica, la riabilitazione del paziente ipovedente e la sua principale attività riguarda l’esecuzione di esami di diagnostica strumentale nel campo della Retina medica, sia nell’attivita ambulatoriale che nell’attivita di ricerca.


Formazione

2009  Laurea con lode in Ortottica e assistenza oftalmologica, presso  L’Università di Roma Tor Vergata

Ruoli

  • Dal 2010 al 2012 Borsista Linea di Ricerca Retina medica
  • Dal 2013 al 2015 Contrattista Linea di Ricerca Retina medica
  • Dal 2016 Dipendente a tempo indeterminato
    Attività di ricerca presso Fondazione G.B.Bietti –IRCCS via livenza 3, 00198 Roma
    Attività assistenziale presso il centro per le maculopatie della Fondazione G.B.Bietti-IRCCS presso la ASL complesso ospedaliero S.Giovanni -Addolorata, Via di santo Stefano Rotondo 6, Roma
  • A 12-month, phase IIb, randomized, single-masked, multicenter study assessing the efficacy and safety of ranibizumab 0.5mg in Treat and Extend regimen compared to Monthly regimen, in patients with neovascular age-related macular degeneration ( TREND)
    Study-coordinator
  • A 12-month, randomized, double-masked, sham-controlled, multicenter study to evaluate the efficacy and safety of 0.5 mg ranibizumab intravitreal injections in patients with visual impairment due to vascular endothelial growth factor (VEGF) driven choroidal neovascularization (CNV) (MINERVA)
    Study- coordinator
  • A PHASE 3 randomized, double-masked, controlled trial to establish the safety and efficacy of intravitreous administration of fovista ( anti pdgf-b pegylated aptamer) administered in combination with Lucentis compared to lucentis monotherapy in subjects with subfoveal neovascular age-related macular degeneration. ( Fovista-OPH1002 )
    Study-coordinator
  • A Phase II multicenter, randomizes, double-maskerd, sham-controlled study to assess the efficacy and safety of lampalizumab administered intravitreally to patents with geographic atrophy secondary to o age-related macular degeneration. (CHROMA)
    Study coordinator
  • A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Either Avastin® or Eylea® Compared to Avastin® or Eylea® Monotherapy (Fovista-OPH1004) 
    Study coordinator
  • Safety and Efficacy of Abicipar Pegol (AGN-150998) in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA)
    Co-investigator
  • An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two different treatment regimens to subjects with neovascular age-related macular degeneration (nAMD) (AZURE)
    Co-investigator
  • Managing neovascular age-related macular degeneration (nAMD) over 2 years with a Treat and Extend (T&E) regimen of 2 mg intravitreal (IVT) aflibercept - a randomized, open-label, active-controlled, parallel-group phase IV/IIIb study (ARIES)
    Co-investigator
  • A multi-center, single-arm, interventional Phase 4 study to evaluate a Treat and Extend regimen of intravitreal aflibercept for treatment of macular edema secondary to central retinal vein occlusion  (CENTERA)
    Co-investigator